Abstract
Accurate prediction of COVID-19 cases can optimize clinical trial recruitment, inform mitigation strategies and facilitate rapid medication development. Here we present a country-specific, modified Susceptible, Exposed, Infectious, Removed (SEIR) model of SARS-CoV-2 transmission using data from the Johns Hopkins University COVID-19 Dashboard. Inter-country differences in initial exposure, cultural/environmental factors, reporting requirements and stringency of mitigation strategies were incorporated. Asymptomatic patients and super-spreaders were also factored into our model. Using these data, our model estimated 65.8% of cases as asymptomatic; symptomatic and asymptomatic people were estimated to infect 2.12 and 5.83 other people, respectively. An estimated 9.55% of cases were super-spreaders with a 2.11-fold higher transmission rate than average. Our model estimated a mean maximum infection rate of 0.927 cases/day (inter-country range, 0.63–1.41) without mitigation strategies. Mitigation strategies with a stringency index value of ≥60% were estimated to be required to reduce the reproduction ratio below 1. It was predicted that cases over the next 2 months would differ between countries, with certain countries likely to experience an accelerated accumulation of cases. Together, results from our model can guide distribution of diagnostic tests, impact clinical trial development, support medication development and distribution and inform mitigation strategies to reduce COVID-19 spread.
Key Findings
Predicting COVID-19 cases can inform medication development and mitigation strategies
We created a modified SEIR model of SARS-CoV-2 transmission
We integrated asymptomatic cases, super-spreaders and hotspots that drive viral spread
Mitigation strategies with a stringency index of ≥60% are required to reduce the RR below 1
Some countries may experience an accelerated accumulation of cases in the coming months
Competing Interest Statement
ALD, JL and ML are employees of Roche Pharmaceuticals, Inc., and receive salary and stock options. BC is an employee of Roche Products Ltd and receives salary and stock options. ACH, PB, SF and JEC are employees of F. Hoffmann-La Roche Ltd and receive salary and stock options.
Funding Statement
This study was funded by F. Hoffmann-La Roche Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Real-world epidemiological data were obtained from the Johns Hopkins University COVID-19 Center for Systems Science and Engineering COVID-19 Dashboard on 31 August 2020. This includes data from national and state government health departments and local media reports. In addition, country-level mitigation data from the Coronavirus Government Response Tracker, collected and validated by Oxford University, were used to investigate the potential mitigation impact of NPIs on the transmission of SARS-CoV-2, with the objective of building country-specific quantitative relationships between NPIs and transmission model parameters.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).